Table SI. Patients' information of drug-resistant and -sensitive prolactinomas.

No.	Subtype	Sex	Age	Clinical presentation	Cavernous sinus invasion	Max diameter (cm)	Prolactin levels (Before surgery ng/ml)	Prolactin levels (before DA treatment, ng/ml)	Prolactin levels (after DA treatment, ng/ml)
1	PRL(DS)	M	62	Headache	L.CS	2.3	3845.64	196.83	19.59
2	PRL(DS)	M	51	Headache, hyposexulality	L.CS	3.4	1602.3	380.42	3.3
3	PRL (DS)	M	32	Headache	L.CS	1.5	786.82	37.41	7.4
4	PRL (DS)	M	49	Headache, hyposexulality	R.CS	2	308.19	7.98	12.3
5	PRL (DS)	F	27	Amenorrhea	None	1.2	72.71	3.16	8.6
6	PRL (DS)	M	51	None	R.CS	32	895.63	443.25	26.85
7	PRL (DR)	F	40	Menstrual disorders	Non-invasive	9	988.22	145.32	86.3
8	PRL (DR)	F	23	Menstrual disorders	Non-invasive	12	721.34	265.34	147.15
9	PRL (DR)	M	16	Blurred vision	L.CS	62	7580.45	7990.26	1721.76
10	PRL (DR)	M	70	Headache with vision loss	L.CS	45	2781.76	49.5	53.2
11	PRL (DR)	F	51	Blurred vision	L.CS	27	326.42	213.72	121.6
12	PRL (DR)	F	32	Menstrual disorders	L.CS	24	4218.1	592.01	674.63
13	PRL (DR)	F	24	Amenorrhea	R.CS	11	365.35	62.65	53.3
14	PRL (DR)	M	32	Sexual dysfunction	L.CS	23	227.64	92.44	88.46
15	PRL(DR)	F	36	Menstrual disorders	Non-invasive	NA	1172.64	52.47	NA
16	PRL (DR)	M	21	Visual field defect	L.CS	33	414.11	32.86	329.26
17	PRL (DR)	M	26	None	R.CS	31	1041.71	78.78	62.38
18	PRL (DR)	M	46	Visual impairment	L.CS	28	916.01	96.63	102.4
19	PRL (DR)	F	24	Amenorrhea	R.CS	33	5472.4	157.21	172.8
20	PRL (DR)	M	32	Visual impairment	Non-invasive	38	1576.39	134.84	108.2

M, male; F, female; DR, drug resistance; DS, drug sensitivity; L.CS, left cavernous sinus; R.CS, right cavernous sinus.

Table SII. Clinical and immunohistochemical characteristics of human clinically pituitary adenomas (219).

No	PAs type	Sex	Age at onset (years)	Knosp Grade	Maximum diameter (mm)	Recurrence	TSH	FSH	ACTH	LH	PRL	GH	Ki-67 (%)	SF-1	TBX19	Silencing ACTH
1	GH	F	57	1	9	No	-	-	-	-	+	+	1%	-	-	-
2	GH	M	31	1	9	No	NA	NA	NA	NA	NA	-	NA	-	-	-
3	GH	M	26	NA	21	No	-	-	-	-	+	+	<1%	-	-	-
4	GH	F	43	4	31	Yes	-	-	-	-	-	+	2%	-	-	-
5	GH	F	33	3	32	No	-	-	-	-	Rare	+	1%	-	-	-
6	PRL	M	20	3	31	Yes	-	-	-	-	+	+	2%	-	-	-
7	GH	F	40	2	10	No	-	-	-	-	+	+	2%	-	-	-
8	GH	F	41	4	29	Yes	-	-	-	-	Rare	+	1%	-	-	-
9	GH	F	48	3	20	No	-	-	-	-	Rare	+	1%	-	-	-
10	GH	F	49	1	23	No	+	-	-	-	+	+	3%	+	-	-
11	GH	M	26	4	24	No	-	-	-	-	+	+	<1%	-	-	-
12	GH	M	61	3	18	No	+	-	-	-	+	+	<2%	-	-	-
13	GH	F	54	2	17	No	-	-	-	-	-	+	1%	-	-	-
14	GH	F	46	3	12	No	-	-	-	-	+	+	3%	-	-	-
15	GH	F	46	2	21	No	-	+	-	-	-	+	3%	-	-	-
16	GH	M	47	3	32	No	-	-	-	-	+	+	2%	-	-	-
17	GH	M	21	2	32	No	-	-	-	+	+	+	2%	-	-	-
18	GH	F	22	3	28	Yes	-	-	-	-	-	+	3%	-	-	-
19	GH	F	51	4	20	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
20	GH	F	40	2	14	No	+	+	-	+	+	+	3%	-	-	-
21	GH	F	26	3	31	Yes	+	-	-	Rare	+	+	1%	-	-	-
22	GH	M	21	1	11	No	-	-	-	-	-	+	2%	-	-	-
23	GH	M	30	2	19	Yes	-	-	-	-	+	+	3%	-	-	-
24	GH	M	31	3	10	No	-	-	-	+	+	+	2%	-	-	-
25	GH	M	63	1	16	No	-	-	-	-	+	+	3%	-	-	-
26	GH	M	52	2	44	Yes	-	-	-	-	-	+	1%	-	-	-
27	GH	M	51	2	11	NA	-	-	-	-	+	+	3%	-	-	-
28	GH	F	18	2	28	NA	-	-	-	-	-	+	5%	-	-	-
29	GH	M	32	2	9	Yes	+	-	-	-	+	+	2%	-	-	-
30	GH	M	51	1	4	No	-	-	-	-	+	+	1%	-	-	-
31	NFPA	M	29	4	11	No	-	-	+	-	-	-	3%	-	+	+
32	PRL	M	66	3	33	No	-	-	-	Rare	+	+	5%	-	-	-
33	NFPA	M	60	3	17	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
34	NFPA	F	61	2	26	No	-	+	-	-	-	-	0%	+	-	-

35	PRL	F	20	1	10	NA	-	-	-	-	+	-	2%	-	-	-
36	PRL	M	58	3	45	No	-	-	-	-	+	Rare	3%	-	-	-
37	PRL	F	21	1	9	NA	-	-	-	-	+	-	5%	-	-	-
38	PRL	M	25	1	16	No	-	-	-	-	+	-	3%	-	-	-
39	PRL	M	29	2	20	NA	-	-	-	-	+	-	5%	-	-	-
40	PRL	F	24	1	10	No	-	-	-	-	+	-	NA	-	-	-
41	PRL	F	21	1	9	No	-	-	-	-	+	-	5%	-	-	-
42	PRL	M	20	2	24	No	-	-	-	+	+	-	10%	-	-	-
43	PRL	F	24	1	13	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
44	PRL	M	18	3	29	No	-	-	-	-	+	-	15%	-	-	-
45	PRL	M	41	1	3	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
46	NFPA	M	39	1	14	No	-	+	-	-	-	-	1%	-	-	-
47	NFPA	M	73	4	31	NA	-	-	+	-	-	-	3%	-	+	+
48	NFPA	M	63	2	18	NA	-	+	-	-	-	-	0%	+	-	-
49	NFPA	F	38	3	20	NA	-	-	+	-	-	-	1%	-	+	+
50	NFPA	M	31	2	39	NA	-	-	+	-	-	-	1%	-	+	+
51	NFPA	F	30	1	17	No	-	-	+	-	-	-	NA	-	+	+
52	NFPA	M	37	3	39	Yes	-	+	-	+	-	-	0%	+	-	-
53	NFPA	M	71	3	23	NA	-	+	-	-	-	-	0%	+	-	-
54	NFPA	M	36	3	31	No	-	+	-	-	-	-	0%	+	-	-
55	NFPA	M	71	3	29	No	-	+	-	-	-	-	2%	+	-	-
56	NFPA	F	64	3	52	No	-	-	+	-	-	-	0%	-	+	+
57	NFPA	M	46	2	27	No	-	+	-	-	-	-	0%	+	-	-
58	NFPA	F	26	4	45	Yes	-	-	+	-	-	-	1%	-	+	+
59	NFPA	F	53	4	36	No	-	-	+	-	-	-	0%	-	+	+
60	NFPA	M	34	2	21	No	-	+	-	-	-	-	0%	+	-	-
61	NFPA	M	53	3	26	No	-	+	-	-	-	-	0%	+	-	-
62	NFPA	F	25	2	20	No	+	-	-	-	+	+	0%	-	-	-
63	NFPA	F	27	2	33	No	+	+	-	-	+	-	0%	+	-	-
64	NFPA	F	40	4	32	No	-	-	+	-	-	-	0%	-	+	+
65	NFPA	M	53	1	19	No	-	+	-	-	-	-	1%	+	-	-
66	NFPA	F	52	1	15	No	-	+	-	-	+	-	1%	+	-	-
67	NFPA	F	40	3	36	Yes	-	+	-	-	-	-	6%	+	-	-
68	NFPA	M	54	2	17	No	-	+	-	-	-	-	0%	+	-	-
69	NFPA	M	60	1	20	No	-	+	-	-	-	-	0%	+	-	-
70	NFPA	M	32	2	24	No	-	+	-	-	-	-	0%	+	-	-
71	NFPA	M	42	2	17	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
72	NFPA	F	54	4	35	NA	-	-	+	-	-	-	1%	-	+	+
73	NFPA	M	37	3	25	No	-	+	-	-	-	-	0%	+	-	-

74	NFPA	M	60	3	20	No	-	+	-	-	-	-	1%	+	-	-
75	NFPA	F	48	2	18	No	-	-	+	-	-	-	0%	-	+	+
76	NFPA	M	61	3	19	No	-	+	-	-	-	-	0%	+	-	-
77	NFPA	M	60	3	27	No	-	+	-	-	-	-	0%	+	-	-
78	NFPA	M	60	2	14	No	-	+	-	-	-	-	0%	+	-	-
79	NFPA	M	66	3	25	No	-	+	-	-	-	-	1%	+	-	-
80	NFPA	M	58	3	21	No	-	+	-	-	-	-	0%	+	-	-
81	NFPA	F	59	2	17	No	-	-	+	-	-	-	0%	-	+	+
82	NFPA	M	73	1	20	No	-	+	-	-	-	-	0%	+	-	-
83	NFPA	F	55	1	21	No	-	+	-	-	-	-	0%	-	-	-
84	NFPA	F	41	2	29	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
85	NFPA	F	55	3	19	No	-	-	+	-	-	-	0%	-	+	+
86	NFPA	F	46	2	25	NA	-	-	+	-	-	-	0%	-	+	+
87	NFPA	F	34	1	21	No	-	-	-	-	+	+	5%	-	-	-
88	NFPA	F	66	3	27	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
89	NFPA	F	61	1	15	No	+	-	-	-	+	+	0%	-	-	-
90	NFPA	F	32	4	52	Yes	-	-	-	-	-	-	3%	-	+	+
91	NFPA	F	55	2	21	No	-	+	-	-	-	-	0%	+	-	-
92	NFPA	F	56	2	30	No	-	+	-	-	-	-	0%	+	-	-
93	NFPA	F	46	2	23	No	-	-	+	-	+	-	0%	-	+	-
94	NFPA	F	60	4	60	No	-	-	-	-	-	-	1%	+	+	+
95	NFPA	M	38	4	32	Yes	-	+	-	-	-	-	1%	+	-	-
96	NFPA	M	52	2	16	No	-	+	-	+	-	-	0%	+	-	-
97	NFPA	M	40	3	21	No	-	+	-	+	+	-	2%	+	-	-
98	NFPA	M	34	3	31	No	-	-	-	+	+	-	1%	-	-	-
99	NFPA	F	68	1	17	No	-	-	-	-	-	-	0%	-	-	-
100	NFPA	F	52	3	20	NA	-	-	+	-	-	-	0%	-	+	+
101	NFPA	M	48	2	19	No	-	+	-	+	-	-	3%	+	-	-
102	NFPA	M	37	4	43	Yes	-	+	-	-	-	-	8%	+	-	-
103	NFPA	M	44	2	13	No	-	+	-	+	-	-	2%	+	-	-
104	NFPA	F	50	2	14	No	+	-	-	-	+	+	2%	-	-	-
105	NFPA	M	63	3	18	No	-	+	-	+	-	-	3%	+	-	-
106	NFPA	M	61	3	25	No	-	+	-	+	-	-	3%	+	-	-
107	NFPA	M	66	3	15	No	+	-	-	+	+	+	1%	-	-	-
108	NFPA	M	50	1	28	No	-	+	-	+	-	-	3%	+	-	-
109	NFPA	M	65	2	23	No	-	+	-	-	-	-	2%	+	-	-
110	NFPA	M	68	3	26	NA	-	+	-	-	-	-	2%	+	-	-
111	NFPA	F	51	3	23	Yes	-	0	-	-	-	+	2%	-	-	-
112	NFPA	M	65	3	34	NA	-	+	-	-	-	-	1%	+	-	-

113	NFPA	F	43	2	26	NA	-	+	-	-	-	-	3%	+	-	-
114	NFPA	F	65	3	36	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
115	NFPA	M	44	2	46	No	-	+	-	+	-	-	3%	+	-	-
116	NFPA	M	52	2	46	No	-	+	-	+	-	-	2%	+	-	-
117	NFPA	M	66	4	24	NA	-	+	-	-	-	-	2%	+	-	-
118	NFPA	M	66	3	9	No	-	+	-	-	-	-	2%	+	-	-
119	NFPA	M	40	2	35	No	-	+	-	-	-	-	10%	-	-	-
120	NFPA	M	44	2	14	No	-	+	-	-	-	-	2%	+	-	-
121	NFPA	F	37	3	21	No	+	+	-	-	-	+	2%	-	-	-
122	NFPA	F	28	4	29	Yes	-	-	+	-	-	-	10%	-	+	+
123	NFPA	F	53	3	33	Yes	-	+	-	+	-	-	3%	+	-	-
124	TSH	F	35	0	4	Yes	+	-	-	-	-	-	＜1%	-	-	-
125	TSH	M	50	1	14	No	+	-	-	-	+	+	5%	-	-	-
126	NFPA	M	26	4	26	Yes	-	-	+	-	-	-	1%	-	+	+
127	ACTH	F	56	3	42	Yes	-	-	-	-	-	-	0%	-	+	+
128	ACTH	F	42	1	15	NA	-	-	+	-	-	-	1%	-	+	-
129	ACTH	F	53	3	29	Yes	-	-	+	-	-	-	6%	-	+	-
130	PRL	M	9	NA	16	Yes	-	-	+	+	+	+	＜1%	-	-	-
131	PRL	F	26	4	56	Yes	+	-	-	+	+	+	0%	-	-	-
132	NFPA	F	46	3	20	Yes	-	+	-	+	-	-	5%	+	-	-
133	NFPA	F	21	1	12	No	-	-	-	-	+	-	1%	-	-	-
134	NFPA	F	61	3	29	NA	-	-	+	-	-	-	3%	-	+	+
135	NFPA	F	48	3	22	NA	-	-	+	-	-	-	1%	-	+	+
136	NFPA	M	53	2	29	NA	-	+	-	+	-	-	1%	+	-	-
137	GH	F	38	2	20	Yes	-	+	-	-	+	+	＜1%	-	-	-
138	NFPA	M	36	3	31	NA	-	+	-	-	-	-	2%	+	-	-
139	NFPA	F	25	1	18	No	-	+	-	-	-	-	3%	+	-	-
140	NFPA	F	71	3	19	NA	-	+	-	-	+	-	2%	+	-	-
141	ACTH	F	21	NA	3	NA	-	-	+	-	-	-	2%	-	+	-
142	NFPA	M	33	NA	42	NA	-	+	-	-	-	-	3%	+	-	-
143	ACTH	F	33	4	28	NA	-	-	+	-	-	-	1%	-	+	+
144	NFPA	F	33	4	34	Yes	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
145	NFPA	F	50	2	17	No	-	+	-	-	-	-	2%	+	-	-
146	PRL	F	33	1	8	No	-	-	-	-	+	-	8%	-	-	-
147	GH	F	34	4	53	Yes	-	-	-	-	+	+	1%	-	-	-
148	PRL	F	29	1	8	No	-	-	-	-	+	-	1%	-	-	-
149	GH	M	18	3	36	No	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
150	PRL	M	20	1	29	No	-	-	-	-	+	-	5%	-	-	-
151	NFPA	M	69	2	18	No	-	+	-	-	-	-	1%	+	-	-

152	PRL	F	30	1	10	No	-	-	-	-	+	+	0%	-	-	-
153	ACTH	F	24	4	39	Yes	-	-	+	-	-	-	5%	-	+	-
154	GH	M	33	3	26	NA	-	-	-	-	Rare	+	5%	-	-	-
155	NFPA	M	18	1	10	NA	-	+	-	-	-	-	1%	+	-	-
156	GH	F	48	2	16	No	-	-	-	-	-	+	3%	+	-	-
157	GH	F	61	2	20	No	-	-	-	-	+	+	2%	-	-	-
158	PRL	F	21	4	22	Yes	-	-	-	+	Rare	+	NA	-	-	-
159	NFPA	F	53	3	35	Yes	-	-	+	-	-	-	0%	-	+	+
160	GH	M	24	2	11	No	-	-	-	-	Rare	+	2%	-	-	-
161	NFPA	M	57	1	16	NA	-	+	-	+	-	-	3%	+	-	-
162	NFPA	F	58	4	32	Yes	-	-	+	-	-	-	2%	-	+	+
163	PRL	F	32	2	18	No	-	-	+	-	-	-	NA	-	+	+
164	GH	M	39	2	37	No	+	-	-	+	+	+	2%	-	-	-
165	ACTH	F	30	1	18	No	-	-	+	-	-	-	3%	-	+	-
166	NFPA	F	35	2	18	No	-	+	-	-	-	-	2%	+	-	-
167	NFPA	M	24	2	26	No	-	+	-	+	-	-	2%	+	-	-
168	NFPA	M	55	2	16	No	-	+	-	+	-	-	4%	+	-	-
169	ACTH	F	27	2	2	Yes	+	+	+	+	+	+	1%	+	+	-
170	GH	F	53	2	20	NA	-	-	-	-	-	+	1%	-	-	-
171	NFPA	F	35	3	27	No	-	+	-	+	-	-	2%	+	-	-
172	NFPA	F	37	4	42	NA	-	-	+	-	-	-	1%	-	+	+
173	NFPA	M	36	4	41	NA	-	+	-	+	-	-	2%	+	-	-
174	PRL	F	51	4	51	Yes	-	NA	NA	NA	+	-	5%	-	-	-
175	NFPA	M	49	2	31	NA	+	-	-	+	+	+	5%	-	-	-
176	PRL	M	44	3	28	Yes	-	-	-	-	+	-	5%	-	-	-
177	GH	F	68	1	16	NA	-	Rare	-	+	Rare	+	1%	+	-	-
178	TSH	M	32	NA	11	NA	+	Rare	-	+	-	Rare	2%	-	-	-
179	GH	F	62	1	18	Yes	-	-	-	-	+	+	NA	-	-	-
180	GH	F	60	2	17	Yes	-	+	-	+	-	+	2%	+	-	-
181	NFPA	M	51	2	33	Yes	-	+	-	-	-	-	1%	+	-	-
182	PRL	M	32	1	38	No	-	-	-	-	+	-	NA	-	-	-
183	TSH	F	60	1	8	No	+	-	-	-	+	+	1%	-	-	-
184	GH	F	34	2	29	Yes	-	-	-	-	-	+	2%	-	-	-
185	NFPA	F	38	2	25	NA	-	-	-	-	-	-	3%	-	+	+
186	NFPA	M	57	1	39	NA	-	+	-	-	-	-	6%	+	-	-
187	ACTH	F	27	1	7	NA	-	-	+	-	-	-	20%	-	+	+
188	ACTH	F	41	1	6	NA	-	-	+	-	-	-	3%	-	+	-
189	ACTH	F	59	1	23	NA	-	-	+	-	-	-	5%	-	+	-
190	NFPA	M	80	2	29	NA	-	+	-	+	-	-	2%	+	-	-

191	NFPA	F	34	1	20	NA	-	+	-	-	-	-	2%	+	-	-
192	ACTH	F	27	NA	5	NA	+	+	+	+	+	+	1%	+	+	-
193	ACTH	F	49	4	28	NA	-	-	+	-	-	-	15%	-	+	-
194	NFPA	F	46	3	25	NA	-	-	-	-	-	-	NA	-	-	-
195	NFPA	M	59	2	29	NA	-	+	-	-	-	-	2%	+	-	-
196	GH	F	38	1	12	NA	-	-	-	-	-	+	1%	-	-	-
197	NFPA	F	47	2	22	NA	-	+	-	-	-	-	NA	+	-	-
198	NFPA	F	56	2	16	NA	-	-	+	-	-	-	NA	-	+	+
199	NFPA	F	51	2	25	NA	-	-	-	-	-	-	NA	-	+	+
200	NFPA	M	56	2	19	NA	-	+	-	+	-	-	NA	+	-	-
201	GH	M	23	1	8	NA	-	-	-	-	-	+	10%	-	-	-
202	NFPA	M	42	3	24	NA	-	+	-	-	-	-	2%	+	-	-
203	GH	F	46	1	20	Yes	-	-	-	-	-	+	2%	-	-	-
204	ACTH	M	12	0	5	No	+	+	+	+	+	+	0%	+	+	+
205	NFPA	M	42	2	19	No	-	+	-	+	-	-	3%	+	-	-
206	GH	F	50	1	20	No	-	+	-	+	+	+	0%	-	-	-
207	NFPA	F	55	3	36	No	-	-	-	-	-	-	5%	-	+	+
208	PRL	F	20	1	10	No	-	-	-	-	+	-	5%	-	-	-
209	ACTH	F	39	0	3	No	-	-	+	-	-	-	3%	-	+	-
210	GH	M	61	0	4	No	-	-	-	-	-	+	1%	-	-	-
211	GH	F	33	2	29	No	-	+	-	+	+	+	3%	+	-	-
212	GH	F	35	3	42	Yes	-	-	-	-	+	+	3%	-	-	-
213	ACTH	F	35	0	7	No	-	-	+	-	-	-	5%	-	+	-
214	PRL	M	26	2	33	No	-	-	-	-	+	-	5%	-	-	-
215	GH	M	53	1	15	No	+	-	-	+	+	+	0%	-	-	-
216	ACTH	F	20	0	7	No	-	+	+	+	+	+	2%	-	+	-
217	GH	F	40	1	16	Yes	-	+	-	+	-	+	2%	-	-	-
218	GH	F	52	2	11	Yes	-	-	-	-	+	+	2%	-	-	-
219	ACTH	F	38	0	6	Yes	-	-	+	-	-	-	0%	-	+	-

NA, the value was not detected or missed; PAs, pituitary adenomas; ACTH, adrenocorticotropic hormone; M, male; F, female; GH, growth hormone; PRL, prolactin.

Table SIII. Primer sequence used in the manuscript.

Species	Symbol	Sequence (5'-3')
Human	circOMA1	Forward: ACCCAAGATGCCAGAATGGT
Human	circOMA1	Reverse: TTGATGACAGCCCCGTGAG
Human	pre-circOMA1	Forward: CGGTTCCTCTCTTGTTGA
Human	pre-circOMA1	Reverse: GTAGCTTGCTCCTTCCTG
Human	GAPDH	Forward: GCGAGATCCCTCCAAAAT
Human	GAPDH	Reverse: GTCCTTCCACGATACCAA
Human/Rat	miR-145-5p	Forward: ATGTCCAGTTTTCCCAGGAATC
Human/Rat	miR-145-5p	Reverse: Provided by the Mir-X™ miRNA First Strand Synthesis Kit (Takara)
Rat	U6	Forward: CCTGCTTCGGCAGCACATATACT
Rat	U6	Reverse: ACGCTTCACGAATTTGCGTGTC
Rat	KBTBD7	Forward: ACCCCTTTCTCTGTTATGA
Rat	KBTBD7	Reverse: CTATTTTGGGCTGGTTTAT
Rat	GAPDH	Forward: GAAGGTCGGTGTGAACGGAT
Rat	GAPDH	Reverse: CCCATTTGATGTTAGCGGGAT
Rat	DRD2	Forward: TCAATGGGTCAGAAGGGAA
Rat	DRD2	Reverse: GATGAGGAGGGTGAGCAGC
Rat	PRL	Forward: TTGAAGGGATTGAAAAGAT
Rat	PRL	Reverse: TTGTGACCAAACCAAGTAG
Rat	Pit-1	Forward: GACTTCATTATTCTGTGCCTTCC
Rat	Pit-1	Reverse: GCTCTTCCACCAATTTACTTTTC
Rat	KBTBD7-sgRNA1	Forward: CACCGAGTATATGAATACGACACTA
Rat	KBTBD7-sgRNA1	Reverse: AAACTAGTGTCGTATTCATATACTC
Rat	KBTBD7-sgRNA2	Forward: CACCGCTTCAAGAGCATGTTCACAG
Rat	KBTBD7-sgRNA2	Reverse: AAACCTGTGAACATGCTCTTGAAGC
Rat	Rab5a	Forward: AGCAACAAGACCCAACGG
Rat	Rab5a	Reverse: TAGAAAGGCAGCCCCAAT
Rat	Rab5b	Forward: CGATACCACAGTTTAGCC
Rat	Rab5b	Reverse: CCTCTTCATACTCCACCA
Rat	Rab5c	Forward: TACATTTGCACGGGCTAA
Rat	Rab5c	Reverse: TCCACACCTCTGTTTCGG
Rat	Rab7a	Forward: GAAAGTGTTGCTGAAGGT
Rat	Rab7a	Reverse: CAAGGGTTTTGAATGTGT
Rat	Rab9a	Forward: TGAGGACACCATTTTACC
Rat	Rab9a	Reverse: ATACCTGCCGTTCTTTTA
Rat	Rab11a	Forward: ACGATGGCTGAAAGAACT

Rat	Rab11a	Reverse: GTGGGTGGGACATGAATA
Rat	Rab14	Forward: CCTCACCAACCCAAACAC
Rat	Rab14	Reverse: CACCAGACTCGGCAGCAT
Rat	Rab27a	Forward: GGGTTTCCTGCTTCTGTT
Rat	Rab27a	Reverse: GGCTTCCTCCTCTTTCAC
Rat	Rab27b	Forward: TATGACACACAAGGAGCA
Rat	Rab27b	Reverse: AACATTAGTAAGAAGCCC
Rat	Rab31	Forward: ACGGGAGTTGGGAAATCA
Rat	Rab31	Reverse: TACATGGGAGCCAGGGAA
Rat	Rab35	Forward: CTTCCGCACCATCACCTCTA
Rat	Rab35	Reverse: GCGTCTTCTGTCTCTACCAC

Table SIV. Antibodies used in the manuscript.

Antibodies	Cat. no.	Company	Dilution ratio
KBTBD7	30914	Signalway Antibody LLC	1:1,000 (WB)
KBTBD7	MG881391	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB); 1:100 (IF, IHC)
ALIX	T57215	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB)
CD9	T55337	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB)
CD63	TD2305	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB)
TSG101	T55985	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB)
DRD2	TD10211S	Abmart Pharmaceutical Technology Co., Ltd.	1:1,000 (WB); 1:100 (IF, IHC)
DRD2	DF10211	Affinity Biosciences	1:1,000 (WB); 1:100 (IF, IHC)
Pit-1	DF13833	Affinity Biosciences	1:100 (IHC)
LC3B	2775	Cell Signaling Technology, Inc.	1:1,000 (WB)
UB	A19686	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
Anti-Rabbit IgG Light Chain	AS061	ABclonal Biotech Co., Ltd.	1:5,000 (WB)
ABflo™ 647-conjugated Goat Anti-Rabbit IgG (H+L)	AS060	ABclonal Biotech Co., Ltd.	1:100 (IF)
CD9	NHA009-A488	NanoFCM Co., Ltd.	1:100 (Fluorescent nanoflow)
CD63	NHA063-AF647	NanoFCM Co., Ltd.	1:100 (Fluorescent nanoflow)
ERK1/2	A4782	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
P-ERK1/2	AP0974	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
Pan-AKT	A18675	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
P-AKT (S473)	AP1208	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
HSP70	A12948	ABclonal Biotech Co., Ltd.	1:1,000 (WB)
Pit-1	A17976	ABclonal Biotech Co., Ltd.	1:500 (WB)
F-actin	RM02835	ABclonal Biotech Co., Ltd.	1:80 (IF)
PRL	16525	Proteintech Group, Inc.	1:1,000 (WB); 1:100 (IHC)
GAPDH	10494	Proteintech Group, Inc.	1:5,000 (WB)
β-actin	20536	Proteintech Group, Inc.	1:1,000 (WB)

WB, western blotting; IHC, immunohistochemistry; IF, immunofluorescence.